NCT06068465招募中3 期
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 248
- 试验地点
- 27
- 主要终点
- The primary outcome is change in total SAPS-PD score from baseline to day 43.
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
详细描述
Not provided
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female of 40 years of age or older;
- •A clinical diagnosis of Parkinson's disease with a minimum duration of 1 year;
- •Subjects must have had psychotic symptoms that developed after the diagnosis of Parkinson's disease was established. These symptoms must have included visual hallucinations and/or auditory hallucinations, and/or delusions；
- •Psychotic symptoms were to have been present for at least one month and the subject must have been actively experienced psychotic symptoms each week during the month prior to the Screening visit;
- •Symptoms severe enough to warrant treatment with an antipsychotic agent; documented at screening by items A and B of the NPI, and defined as a score of 4 or greater on either the Hallucinations (Frequency x Severity) or Delusions (Frequency x Severity) scales OR a total combined score of 6 or greater;
- •At the baseline visit, subject must have had a SAPS Hallucinations or Delusions global item (H7 or D13) score ≥3 AND a score >3 on at least one other non-global item using the modified 9-item SAPS Hallucinations and Delusions domains;
- •Subject must have had a clear sensorium at study entry (i.e., oriented to time, person, and place);
- •Subject must have been on stable dose of anti-Parkinson's medication for 1 month prior to Day 1 (Baseline) and during the trial;
- •If a Subject had received stereotaxic surgery for sub-thalamic nucleus deep brain stimulation they must have been at least 6 months post-surgery and the stimulator settings must have been stable for at least 1 month prior to Day 1 (Baseline) and must remain stable during the trial;
- •Subjects of reproductive age (male/female) must have agreed to use a clinically acceptable method of contraception for at least one month prior to randomization, during the study, and one month following completion of the study;
- •The subject was required to be willing and able to provide consent;
- •Caregiver was required to be willing and able to provide consent and agrees to accompany the subject to all visits.
排除标准
- •Subject with psychotic symptoms (hallucinations and delusions) which could be better explained as a part of a toxic, metabolic or infection-induced delirium /encephalopathy , psychosis due to substance abuse, psychosis associated with schizophrenia, bipolar disorder or psychotic depression;
- •Subject who was likely to have an allergy or sensitivity to pimavanserin based on known allergies to drugs of the same class;
- •Subject who had previously been randomized in any prior clinical study with pimavanserin, and/or received of any other investigational;
- •Subject with a history of significant psychotic disorders prior to or concomitantly with the diagnosis of Parkinson's disease including, but not limited to, schizophrenia or bipolar disorder;
- •Subjects had a significant risk of excitability or committing suicide based on the investigator's judgement; Any suicidal behavior in the year prior to or during screening; Subjects with a Columbia-Suicide Severity Rating Scale (C-SSRS) positive response to suicidal ideation items 4, or 5 are not eligible during the screening period.
- •Subject with atypical Parkinsonism (Parkinson's plus, MSA, PSP), or secondary parkinsonism variants such as tardive or medication induced parkinsonism;
- •Subject who had received previous ablative stereotaxic surgery (i.e., pallidotomy and thalamotomy) to treat Parkinson's disease;
- •Had a score on the Mini-Mental State Examination (MMSE) of <21;
- •Subject who had dementia prior to or concomitantly with the diagnosis of Parkinson's disease that may be inconsistent with a PD diagnosis;
- •Subject who had history of cerebrovascular ischemic syndrome (stroke) that impairs their ability to complete the MMSE;
- •Subject who was using any of the medications prohibited or restricted as described in(Prohibited and Restricted Concomitant Medications-below);
- •Subject who was on medications of antidepressant/anxiety known to prolong the QT interval, the dose of medication cannot be maintained for 21 days before the baseline period;
- •Subject who was on medications of acetylcholinesterase inhibitors，the dose of medication was not guaranteed to remain constant between the first 21 days of the baseline period and the last visit；
- •Subject who had current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder, including cancer or malignancies,which would affect the subject's ability to participate in the study;
- •Subject who had a myocardial infarction in last six months or who had moderate to severe congestive heart failure (NYHA class III or IV);
- •Subject who had a screening and baseline electrocardiogram (ECG) with Bazett's corrected QT (QTcB) of greater than 460 msec if male or 470 msec if female or Subject who was known history or symptoms of long QT syndrome;
- •Alanine aminotransferase (ALT) or glutamic aminotransferase (AST) or total bilirubin (TBiL) in laboratory tests were higher than 2 times the upper limit of normal during screening or baseline. Or severe impairment of renal function (defined as creatinine clearance Ccr < 30 ml/min. Creatinine clearance was calculated according to the Cockcroft-Gault formula); or other abnormal indicators in laboratory tests have clinical significance and are judged by the investigators to have safety risks;
- •Subject who was pregnant or breastfeeding.，female subjects of childbearing potential who have positive pregnancy test results；
- •Subject who had any surgery planned during the screening, treatment or follow-up periods;
- •Subject who had participated in any clinical trial and used investigational drug within 4 weeks prior to enrollment；
- •The investigator considered that the subjects had poor compliance or other factors that made it inappropriate to participate in the clinical trial.
研究组 & 干预措施
Pimavanserin tartrate
Experimental
Pimavanserin, 34 mg, capsule,once daily by mouth for 6 weeks Interventions
干预措施: pimavanserin tartrate (Drug)
Placebo
Placebo Comparator
Placebo, capsule, once daily by mouth for 6 weeks
干预措施: placebo (Drug)
结局指标
主要结局
The primary outcome is change in total SAPS-PD score from baseline to day 43.
时间窗: Assessments are done at baseline and days 15,29 and 43.
Antipsychotic Efficacy was defined as a decrease in the severity and/or frequency of hallucinations and/or delusions. This is measured as the change from baseline (Day 1) to Day 43 in the Scale for the Assessment of Positive Symptoms 9-item sum score for Parkinson's Disease (SAPS-PD). The possible total score is 0 to 45 and a negative change in score indicates improvement. Analysis Method: Analysis of Covariance,ANCOVA
次要结局
未报告次要终点
研究者
研究点 (27)
Loading locations...
相似试验
已完成
3 期
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease PsychosisParkinson's Disease PsychosisNCT01174004ACADIA Pharmaceuticals Inc.199
已完成
3 期
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseNeuropsychiatric Symptoms Related to Neurodegenerative DiseaseNCT03575052ACADIA Pharmaceuticals Inc.784
已完成
3 期
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisParkinson's Disease PsychosisNCT00477672ACADIA Pharmaceuticals Inc.298
已完成
2 期
A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease PsychosisAlzheimer's Disease PsychosisNCT02035553ACADIA Pharmaceuticals Inc.181
已完成
2 期
Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)Adjunctive Treatment of Major Depressive DisorderNCT03018340ACADIA Pharmaceuticals Inc.207